logologo
Search anything
Ctrl+K
arrow
WhatsApp Icon

Coforge stock jumps as RBI clears $1bn Encora ODI deal

COFORGE

Coforge Ltd

COFORGE

Ask AI

Ask AI

Key development: RBI clears overseas investment

Coforge Ltd. said it has received the Reserve Bank of India’s approval for an overseas direct investment exceeding $1,000 million, a regulatory step tied to its acquisition of Encora. The company disclosed the update in an exchange filing, noting the approval is under the Foreign Exchange Management (Overseas Investment) Rules. The clearance relates to Coforge’s proposed transaction involving Encora US Holdco Inc. and Encora Holdings Ltd., as described in reports citing the filing. The RBI approval removes a major procedural hurdle for funding and executing the cross-border component of the deal. Coforge said it will update stock exchanges as additional approvals come in. The company added that remaining clearances are in advanced stages. The transaction, announced in December 2025, still requires approvals in multiple jurisdictions.

How the market reacted on 1 April

Coforge shares rose sharply after the RBI approval became public. One market update noted the stock surged as much as 6% on 1 April. Another report described the stock up 3.8% at 1,157.10 rupees on NSE during the session. A separate data point in the coverage said that at 12:40 pm, Coforge was trading 4.86% higher at Rs 1,168.90 on NSE. These intraday variations reflect different time stamps and sources, but the direction of move was consistent. The price action came amid broader attention on large IT services deal-making. Investors typically track regulatory approvals closely because they determine whether deal timelines can hold. In this case, RBI’s ODI approval was interpreted as a meaningful milestone in the process.

The Encora acquisition: size, structure, and status

Coforge’s acquisition of US-based AI solutions provider Encora has been reported as a $1,350 million deal. The transaction was announced in December 2025 and is subject to further regulatory approvals in other countries. Coforge has already received permission from US antitrust authorities, shareholders, and certain international competition agencies, including in Australia, according to the updates. The company has indicated that remaining approvals are nearing completion. The deal has also been described as India’s biggest IT acquisition, based on the size disclosed in the reports. As with most cross-border transactions, the closing depends on satisfying conditions precedent across jurisdictions.

What Coforge told exchanges

In its filing, Coforge said it had received RBI approval for ODI exceeding $1,000 million. The company’s wording, as reported, stated: it had obtained the central bank’s approval for overseas direct investment exceeding USD one billion under the applicable overseas investment rules. Coforge positioned the approval as an additional key regulatory permission for the ongoing acquisition. It also said it would inform exchanges once remaining approvals are received. The disclosures did not provide a definitive closing date in the coverage provided. However, one report said the transaction is expected to close soon.

Funding: preference shares, equity value, and other reported components

A market note linked to the deal described how Coforge funded the $1,890 million equity value portion through the issue of preference shares at Rs 1,815.91 per share. The same update said Encora shareholders will receive a 20% stake in the combined entity. Separately, another report described the acquisition funding plan as a $1,900 million share sale alongside a $150 million qualified institutional placement (QIP). These figures were reported in different pieces of coverage included in the source text. Together, they highlight that the financing involves equity-linked components and ownership participation for Encora’s shareholders. Investors will typically watch for final terms, post-closing shareholding, and any impact on leverage or dilution once the full documentation is available.

Strategic rationale: healthcare and high-tech focus

The deal is expected to expand Coforge’s presence in the high-tech and healthcare segments. The coverage stated that each of these verticals is estimated to generate about $170 million in sales after the merger. For Coforge, vertical mix matters because it influences margins, client concentration, and the durability of demand across cycles. Encora has been described as an AI firm and AI solutions provider in the reports, aligning with client interest in automation and AI-led delivery models. Coforge’s stated intent, based on the reported narrative, is to gain a stronger footprint in targeted sectors rather than only add scale. The integration outcome will determine whether these sales estimates materialise.

Revenue ambition reported for FY27 timeline

One report said the acquisition is expected to boost Coforge’s revenue to $1,000 million annually by March 2027. That figure was presented as an expected outcome tied to the deal closing and subsequent integration. The report did not provide interim milestones or a detailed bridge between current revenue and the FY27 target in the text provided. Even so, the FY27 reference places the acquisition in a multi-year growth plan. Investors generally evaluate such targets alongside execution risk, client retention, and synergy delivery, especially in services businesses where attrition and delivery capacity can affect outcomes.

Context: Coforge’s recent large client win

Separate coverage included in the source text pointed to Coforge’s largest client win: a $1,560 million, 13-year software product delivery deal with Texas-based travel technology company Sabre. The mention of this deal was used to frame Coforge as outperforming peers on sequential growth in 2025, despite a softer environment for the broader IT services industry. While the Encora deal is an inorganic growth step, the Sabre contract shows the company is also pursuing large organic wins. The combination of large contracts and acquisitions can change revenue composition and delivery complexity. For investors, this context matters when assessing whether Coforge can integrate Encora while maintaining performance on existing commitments.

Market impact: what is known, and what remains pending

The immediate market impact in the source text was a positive move in Coforge’s share price following RBI approval. From a regulatory standpoint, RBI clearance is a prerequisite for an ODI of this size, so the approval reduces uncertainty around the India-side capital movement for the transaction. However, the deal still needs a few more permits from various countries, and that remaining timeline is a key variable. The company has said those approvals are in advanced stages, but the coverage does not list all jurisdictions. Until closing, investors will continue to monitor updates on regulatory milestones and final transaction steps.

Key facts table

ItemDetails reported in source text
CompanyCoforge Ltd. (NSE: COFORGE)
Sector / IndustrySoftware & IT Services / IT Services & Consulting
Deal targetEncora (US-based AI solutions provider)
Acquisition value$1,350 million
RBI approvalODI exceeding $1,000 million under FEMA (Overseas Investment) Rules
Other approvals mentionedUS antitrust authorities, shareholders, competition agencies including Australia
Vertical sales estimate post-mergerHigh-tech: ~$170 million; Healthcare: ~$170 million
Stock move cited (1 April)Up to 6% intraday; also cited +3.8% to Rs 1,157.10; and +4.86% to Rs 1,168.90 at 12:40 pm
Funding details reportedPreference shares at Rs 1,815.91; Encora shareholders to get 20% stake; also reported $1,900 million share sale + $150 million QIP
Revenue target linked to deal$1,000 million annually by March 2027

Analysis: why RBI clearance matters for the deal

For cross-border acquisitions, RBI’s approval for ODI is a core gating item because it enables the outbound investment flow required for closing. In Coforge’s case, the approval exceeds $1,000 million, which matches the scale of the transaction and signals regulatory comfort with the structure under applicable rules. The approval also comes alongside prior clearances cited in the US and Australia, indicating progress on multiple regulatory fronts. That said, the transaction is not yet closed, and the company has stated that a few more approvals in other countries are still pending. The market’s positive reaction suggests investors view RBI clearance as a step that reduces near-term execution risk. The remaining uncertainty is concentrated around the last set of regulatory sign-offs and the subsequent integration of Encora into Coforge’s operating model.

Conclusion

Coforge’s RBI approval for ODI exceeding $1,000 million is a significant milestone for its $1,350 million Encora acquisition announced in December 2025. The company has said remaining approvals are in advanced stages and it will update exchanges as they arrive. Market participants will now track final regulatory clearances and any definitive closing update, along with details on financing and integration milestones.

Frequently Asked Questions

The stock moved up after Coforge disclosed RBI approval for overseas direct investment exceeding $1,000 million, a key step for closing the Encora acquisition.
The acquisition has been reported as a $2,350 million deal for US-based AI solutions provider Encora.
Reports said Coforge has approvals from US antitrust authorities, shareholders, and certain competition agencies, including in Australia, with other clearances still pending.
Coverage cited preference shares issued at Rs 1,815.91 and a 20% stake for Encora shareholders, and also described a plan involving a $1,900 million share sale and a $550 million QIP.
Reports said the deal would strengthen Coforge in high-tech and healthcare, with each vertical estimated at about $170 million in sales after the merger, and a $2,000 million annual revenue target by March 2027.

Did your stocks survive the war?

See what broke. See what stood.

Live Q4 Earnings Tracker